Cetuximab in the treatment of patients with colorectal cancer

Bibliography

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. Declining death rates reflect progress against cancer. PLoS One 2010;5(3):e9584
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Global cancer statistics. CA Cancer J Clin 2011;61:69-90
   Google Scholar
• GLOBOCAN 2008 World Health Organization International Agency for Research on Cancer. Available from: http://globocan.iarc.fr/ [Accessed 14 February 2011]
   Google Scholar
• Goldberg RM. Lessons learned from the edrecolomab story: how a checkered past became a checkered flag for monoclonal antibodies in colorectal cancer therapy. Onkologie 2005;28:311-12
   PubMed Web of Science ®Google Scholar
• Carpenter G. The biochemistry and physiology of the receptor-kinase for epidermal growth factor. Mol Cell Endocrinol 1983;31:1-19
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-85
   PubMed Web of Science ®Google Scholar
• Lockhart AC, Berlin JD. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol 2005;32:432
   Web of Science ®Google Scholar
• Steele RJ, Kelly P, Ellul B, Eremin O. Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 1990;77:1352-4
   PubMed Web of Science ®Google Scholar
• Kluftinger AM, Robinson BW, Quenville NF, Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol 1992;1:97-105
   PubMedGoogle Scholar
• Sato JD, Kawamoto T, Le AD, Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983;1:511-29
   PubMedGoogle Scholar
• Kawamoto TK, Sato JD, Le A, Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 1983;80:1337-41
   PubMed Web of Science ®Google Scholar
• Masui H, Kawamoto T, Sato JD, Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. J Biol Chem 1984;259:7755-60
   PubMedGoogle Scholar
• Khazaeli MB, LoBuglio A, Falcey J, Low immunogenicity of a chimeric monoclonal antibody IMC-C225, used to treat epidermal growth factor-receptor positive tumor [abstract]. Pro Am Soc Clin Oncol 2000;19:207
   Google Scholar
• Fracasso PM, Burris H III, Arquette MA, A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 2007;13:986-93
   PubMed Web of Science ®Google Scholar
• Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy. Clin Cancer Res 2000;6:747-53
   PubMed Web of Science ®Google Scholar
• Prewett M, Hooper A, Bassi R, Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002;8:994-1003
   PubMed Web of Science ®Google Scholar
• Prewett M, Deevi DS, Bassi R, Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab. Clin Cancer Res 2007;13:7432-40
   PubMed Web of Science ®Google Scholar
• Baselga J, Pfister D, Cooper MR, Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14
   PubMed Web of Science ®Google Scholar
• Pippas AW, Lenz HJ, Mayer RJ, Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy [abstract]. J Clin Oncol 2005;23:3595
   Google Scholar
• Saltz L, Rubin M, Hochster H, Cetuximab plus irinotecan is active in irinotecan-refractory colorectal cancer that expresses epidermal growth factor receptor [abstract]. Proc Am Soc Clin Oncol 2001;20:7
   Web of Science ®Google Scholar
• Saltz LB, Meropol NJ, Loehrer PJ Sr, Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
   PubMed Web of Science ®Google Scholar
• Alekshun T, Garrett C. Targeted therapies in the treatment of colorectal cancers. Cancer Control 2005;12:105-10
   PubMedGoogle Scholar
• Jonker DJ, O'Callaghan CJ, Karapetis CS, Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Hitre E, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17
   PubMed Web of Science ®Google Scholar
• Rougier R, Stroiakovski D, Kohne C, Addition of cetuximab to FOLFIRI in first-line metastatic colorectal cancer (mCRC): updated survival data and influence of KRAS status on outcome in the CRYSTAL study [abstract]. Gastrointestinal Cancers Symposium; 2009. p. 443
   Google Scholar
• Van Cutsem E, Lang I, Folprecht G, Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome [abstract]. J Clin Oncol 2010;28:3570
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Hartmann JT, Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011 [Epub ahead of print; doi: 10.1093/annonc/mdq632]
   Google Scholar
• Folprecht G, Gruenberger T, Hartmann JT, Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study) [abstract]. Gastrointestinal Cancers Symposium; 2009. p. 296
   Google Scholar
• Maughan TS, Adams R, Smith CG, Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy in first-line advanced colorectal cancer : mature results of the MRC COIN trial [abstract]. J Clin Oncol 28:3502
   Google Scholar
• Tveit K, Guren T, Glimelius B, Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the NORDIC VII study, by the Nordic Colorectal Cancer Biomodulation Group [abstract]. Gastrointestinal Cancers Symposium; 2011. p. 365
   Google Scholar
• Tabernero J, Ciardiello F, Rivera F, Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. J Clin Oncol 2010;28(7):1181-9
   PubMed Web of Science ®Google Scholar
• Pfeiffer P, Nielsen D, Bjerregaard J, Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 2008;19(6):1141-5
   PubMed Web of Science ®Google Scholar
• Alberts SR, Sargent DJ, Smyrk TC, Adjuvant mFOLFOX6 with or without cetuxiumab in KRAS wild-type patients with resected stage III colon cancer: results from NCCTG Intergroup Phase III Trial N0147 [abstract]. J Clin Oncol 2010;28:3507
   Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Thibodeau SN, Adjuvant mFOLFOX6 plus or minus cetuximab in patients with KRAS mutant resected stage III colon cancer: NCCTG Intergroup Phase III Trial N0147 [abstract]. J Clin Oncol 2010;28:3508
   Google Scholar
• Trotti A, Colevas AD, Setser A, CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13(3):176-81
   PubMed Web of Science ®Google Scholar
• Siena S, Glynne-Jones R, Adenis A, Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer 2010;116(7):1827-37
   PubMed Web of Science ®Google Scholar
• O'Neil BH, Allen R, Spigel DR, High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007;25:3644-8
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E, Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008;358:1109-17
   PubMed Web of Science ®Google Scholar
• Mitchell EP, Lacouture M, Shearer H, Final STEPP results of prophylacatic versus reactive skin toxicity treatment for panitumumab-related ST in patients with metastatic colorectal cancer [abstract]. J Clin Oncol 2009:27:18s
   Web of Science ®Google Scholar
• Jatoi A, Dakhil SR, Sloan JA, Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor inhibitor-induced rash: results from the North Central Cancer Treatment Group. Oncologist 2010;15:1016-22
   PubMed Web of Science ®Google Scholar
• Jatoi A, Thrower A, Sloan JA, Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist 2010;15(9):1016-22
   PubMed Web of Science ®Google Scholar
• Dueland S, Sauer T, Lund-Johansen F, Epidermal growth factor receptor inhibition induces trichomegaly. Ann Oncol 2005;16(10):1711-12
   Google Scholar
• Agero AL, Dusza SW, Benvenuto-Andrade C, Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;55(3):429-37
   PubMedGoogle Scholar
• Solomon BM, Jatoi A. Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash: a Consecutive Patient Series that Illustrates the Need for Rigorous Palliative Trials. J Palliat Med 2011;14:153-6
   Google Scholar
• Saltz L, Kies M, Abbruzzese JL, The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies [abstract]. Proc Am Soc Clin Oncol 2003;22:817
   Google Scholar
• Van Cutsem E, Humblet Y, Gelderblom H, Cetuximab dose-escalation study in patients with metastatic colorectal cancer with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic and efficacy data of a randomized study [abstract]. Gastrointestinal Cancers Symposium; 2007. p. 237
   Google Scholar
• Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005;97:1221-4
   PubMed Web of Science ®Google Scholar
• Perrin C, Fabre C, Raoul JL, Boucher E. Behavioral disorders secondary to profound hypomagnesemia in a patient given cetuximab for metastatic colorectal cancer hypomagnesemia due to cetuximab treatment. Acta Oncol 2006;45:1135-6
   PubMed Web of Science ®Google Scholar
• Wolf FI, Trapani V, Cittadini A, Maier JA. Hypomagnesaemia in oncologic patients: to treat or not to treat? Magnes Res 2009;22:5-9
   PubMed Web of Science ®Google Scholar
• Chung KY, Shia J, Kemeny NE, Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;20:1803-10
   Web of Science ®Google Scholar
• Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004;351:2883
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Garrett CR, Meropol NJ, Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-7
   PubMed Web of Science ®Google Scholar
• Lenz HJ, Van Cutsem E, Khambata-Ford S, Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;20:4914-21
   Web of Science ®Google Scholar
• Moroni M, Veronese S, Benvenuti S, Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-86
   PubMed Web of Science ®Google Scholar
• Moroni M, Sartore-Bianchi A, Veronese S, Siena S. EGFR FISH in colorectal cancer: what is the current reality? Lancet Oncol 2008;9:402-3
   PubMed Web of Science ®Google Scholar
• Pao W, Wang TY, Riely GJ, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2(1):e17
   PubMed Web of Science ®Google Scholar
• Questions and Answers on the Marketing Authorization for Vectibix, London, 20 September 2007, Doc Ref. EMEA/405113/2007. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500017035.pdf [Accessed 24 January 2011]
   Google Scholar
• Dolgin E. FDA narrows drug label usage. Nature 2009;460(7259):1069
   PubMed Web of Science ®Google Scholar
• De Roock W, Jonker DJ, Di Nicolantonio F, Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304:1812-20
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Martini M, Molinari F, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12
   PubMed Web of Science ®Google Scholar
• Laurent-Puig P, Cayre A, Manceau G, Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009;27:5924-30
   PubMed Web of Science ®Google Scholar
• Rizzo S, Bronte G, Fanale D, Prognostic versus predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev 2010;36:56-61
   PubMed Web of Science ®Google Scholar
• Loupakis F, Pollina L, Stasi I, PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009;27:2622-9
   PubMed Web of Science ®Google Scholar
• Hsu CP, Kao TY, Chang WL, Clinical significance of tumor suppressor PTEN in colorectal carcinoma. Eur J Surg Oncol 2011;37:140-7
   PubMed Web of Science ®Google Scholar
• Ogino S, Nosho K, Kirkner GJ, PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009;27(9):1477-84
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Martini M, Molinari F, PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009;69:1851-7
   PubMed Web of Science ®Google Scholar
• Prenen H, De Schutter J, Jacobs B, PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009;15:3184-8
   PubMed Web of Science ®Google Scholar
• De Roock W, Claes B, Bernasconi D, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11(8):753-62
   PubMed Web of Science ®Google Scholar
• Power DG, Shah MA, Asmis TR, Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience. Invest New Drugs 2010;28:353-60
   PubMed Web of Science ®Google Scholar
• Saif MW, Kaley K, Chu E, Copur MS. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clin Colorectal Cancer 2010;9:315-18
   PubMed Web of Science ®Google Scholar
• Jansman FG, Postma MJ, Brouwers JR. Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics 2007;25:537-62
   PubMed Web of Science ®Google Scholar
• Schrag D. The price tag on progress–chemotherapy for colorectal cancer. N Engl J Med 2004;351:317-19
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, LaFleur B, Levy DE, Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 2005;23:9265-74
   PubMed Web of Science ®Google Scholar
• Townsley CA, Major P, Siu LL, Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 2006;94:1136-43
   PubMed Web of Science ®Google Scholar
• Zhang W, Gordon M, Schultheis AM, FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007;25:3712-18
   PubMed Web of Science ®Google Scholar
• Tol J, Koopman M, Cats A, Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360(6):563-72
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Finocchiaro G, Rossi E, EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008;19:717-23
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Moroni M, Veronese S, Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007;25(22):3238-45
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, Boige V, KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9
   PubMed Web of Science ®Google Scholar
• De Roock W, Piessevaux H, De Schutter J, KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508-15
   PubMed Web of Science ®Google Scholar
• Finocchiaro G, Cappuzzo F, Janne PA, EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer [abstract]. J Clin Oncol 2007;18s:4021
   Google Scholar